BeOne Medicines Ltd.
ONCNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as BEIGF
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026Score 12/302252% above fair value
$361.27−9.06 (-2.45%)
Close on Nov 2, 2026Market cap $41.08BP/E 64.6Yield –
BeOne Medicines BRUKINSA — United States Revenue Growth YoY by Year
BRUKINSA — United States Revenue Growth YoY (%) (%)
BeOne Medicines BRUKINSA — United States Revenue Growth YoY: 45.1% in FY2025, down 61.2 pts from a year earlier.
Latest, FY2025
45.1%
Period ended Dec 31, 2025
Change on a year earlier
-61.2 pts
106.3% in FY2024
History
5 years
Since FY2021
Sources
5
Documents cited below
Where the FY2025 figure comes from
“U.S. sales of BRUKINSA totaled $2.8 billion for the year ended December 31, 2025 compared to $2.0 billion in the prior year, representing growth of 45.1%, driven primarily by robust demand growth across all indications and modest benefit due to net pricing.”
Source: Form 10-K (filed 2026-02-26) ↗
Reported in Form 10-Q / 10-K MD&A & Form 8-K Earnings Releases.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | BRUKINSA — United States Revenue Growth YoY (%) (%) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 45.1% | -61.2 pts | Form 10-K (filed 2026-02-26) ↗ |
| FY2024 | Dec 31, 2024 | 106.3% | -36.3 pts | Form 10-K (filed 2025-02-27) ↗ |
| FY2023 | Dec 31, 2023 | 142.6% | -94.4 pts | Form 10-K (filed 2024-02-26) ↗ |
| FY2022 | Dec 31, 2022 | 237.0% | -298.0 pts | Form 10-K (filed 2023-02-27) ↗ |
| FY2021 | Dec 31, 2021 | 535.0% | – | Form 8-K (filed 2022-02-25) ↗ |
Cite this data
StockData. (2026). BeOne Medicines BRUKINSA — United States Revenue Growth YoY (%), annual FY2021–FY2025 [Data set]. Compiled from BeOne Medicines SEC filings and investor materials. https://stockdatahq.com/stocks/onc/kpis/prod-brukinsa-us-yoy
See every metric in the BeOne Medicines KPI table. Data updated Oct 29, 2026.